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Abstract
 
We have discovered a new and specific cell-killing mechanism mediated by the selective uptake of
the antitumor drug 1-
 
O
 
-octadecyl-2-
 
O
 
-methyl-
 
rac
 
-glycero-3-phosphocholine (ET-18-OCH
 
3
 
,
Edelfosine) into lipid rafts of tumor cells, followed by its coaggregation with Fas death receptor
(also known as APO-1 or CD95) and recruitment of apoptotic molecules into Fas-enriched
rafts. Drug sensitivity was dependent on drug uptake and Fas expression, regardless of the presence
of other major death receptors, such as tumor necrosis factor (TNF) receptor 1 or TNF-related
apoptosis-inducing ligand R2/DR5 in the target cell. Drug microinjection experiments in Fas-
deficient and Fas-transfected cells unable to incorporate exogenous ET-18-OCH
 
3 
 
demon-
strated that Fas was intracellularly activated. Partial deletion of the Fas intracellular domain pre-
vented apoptosis. Unlike normal lymphocytes, leukemic T cells incorporated ET-18-OCH
 
3
 
into rafts coaggregating with Fas and underwent apoptosis. Fas-associated death domain pro-
tein, procaspase-8, procaspase-10, c-Jun amino-terminal kinase, and Bid were recruited into
rafts, linking Fas and mitochondrial signaling routes. Clustering of rafts was necessary but not
sufficient for ET-18-OCH
 
3
 
–mediated cell death, with Fas being required as the apoptosis trigger.
ET-18-OCH
 
3
 
–mediated apoptosis did not require sphingomyelinase activation. Normal cells,
including human and rat hepatocytes, did not incorporate ET-18-OCH
 
3 
 
and were spared. This
mechanism represents the first selective activation of Fas in tumor cells. Our data set a frame-
work for the development of more targeted therapies leading to intracellular Fas activation and
recruitment of downstream signaling molecules into Fas-enriched rafts.
Key words: CD95 • Fas signaling • death receptor • antitumor ether lipid • ET-18-OCH
 
3
 
Introduction
 
A group of synthetic ether-linked lysophospholipid ana-
logs, collectively named antitumor ether lipids, represent a
promising class of anticancer agents that, unlike most con-
ventional chemotherapeutic drugs, do not target the DNA
but act at the level of cell membranes, and therefore their
effects are independent of the proliferative state of target
cells (1–4). The synthetic ether phospholipid 1-
 
O
 
-octadecyl-
2-
 
O
 
-methyl-
 
rac
 
-glycero-3-phosphocholine (ET-18-OCH
 
3
 
,
Edelfosine) selectively induces apoptosis in cancer cells (5)
and has become the effective prototype of antitumor ether
lipids. Because of its ether bonds, ET-18-OCH
 
3 
 
is meta-
bolically stable, resistant to phospholipases, and accumulates
in the plasma membrane (6). The mechanism by which
ET-18-OCH
 
3 
 
selectively engages the suicide apparatus in
tumor cells is still unclear. Persistent activation of the c-Jun
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Abbreviations used in this paper:
 
 CTx, cholera toxin; DISC, death-inducing
signaling complex; ET-18-OCH
 
3
 
, 1-
 
O
 
-octadecyl-2-
 
O
 
-methyl-
 
rac
 
-glycero-
3-phosphocholine; FADD, Fas-associated death domain protein; FasL,
Fas ligand; JNK, c-Jun amino-terminal kinase; SMase, sphingomyelinase;
TLC, thin layer chromatography; TRAIL, TNF-related apoptosis-inducing
ligand; TUNEL, TdT-mediated dUTP nick-end labeling. 
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amino-terminal kinase (JNK) pathway (7, 8) and mito-
chondrial-related processes (9–11) have been involved in
the apoptotic response induced by ET-18-OCH
 
3
 
. We have
recently found that ET-18-OCH
 
3
 
–induced apoptosis is
mediated by the activation of the death receptor Fas (also
known as APO-1 or CD95) independently of its ligand
(FasL, also named CD95L; references 12 and 13) through
its coclustering with membrane rafts (14). This Fas associa-
tion with membrane rafts, further confirmed in subsequent
studies following Fas–FasL interaction (15–17), can be of
major importance in amplifying Fas signaling as lipid rafts
might serve as foci for recruitment of signaling molecules at
the plasma membrane (18). Fas is a member of the TNFR
family that triggers cell death through the presence of a
death domain in its cytoplasmic portion after receptor en-
gagement with FasL or agonistic anti-Fas antibodies (19).
Stimulation of Fas results in receptor oligomerization and
recruitment of the adaptor molecule Fas-associated death
domain protein (FADD) through interaction between its
own death domain and the clustered receptor death do-
mains. In turn, FADD recruits procaspase-8 via a death ef-
fector domain interaction forming the so-called death-
inducing signaling complex (DISC; reference 20). The
close proximity of procaspase-8 molecules in the DISC
drives its activation by self-cleavage, triggering downstream
effector caspases and leading to apoptosis (21). Thus, for-
mation of membrane platforms where Fas molecules are
brought together is suggested to increase DISC formation
and therefore potentiate Fas signaling (13, 14, 16, 17, 22–25).
In this regard, sphingomyelinase (SMase)-derived ceramide
has been recently reported to amplify the signaling of Fas at
the membrane level after the initial Fas–FasL interaction,
acting as a mediator of the clustering of Fas (23, 24, 26).
Here, we show a novel mechanism of drug action in
which ET-18-OCH
 
3 
 
is selectively incorporated into tumor
cell membrane rafts promoting their clustering as well as
translocation of Fas and downstream signaling molecules
into clustered rafts in a SMase-independent manner. ET-
18-OCH
 
3
 
–mediated apoptosis was dependent on intracel-
lular activation of Fas, independently of other major death
receptors such as TNF and TNF-related apoptosis-induc-
ing ligand (TRAIL) receptors. Normal cells, including he-
patocytes and PBLs, were spared because they failed to take
up the ether lipid and thereby failed to trigger the ensuing
apoptotic events.
 
Materials and Methods
 
Cells and Fas Transfectants.
 
The human cell lines HL-60
(acute myeloid leukemia), U937 (histiocytic lymphoma), and
Jurkat (acute T cell leukemia), obtained from the American
Type Culture Collection, were grown as described previously in
RPMI 1640 culture medium supplemented with 10% heat-inac-
tivated FCS, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 24
 
 
 
g/ml gentamicin (5).
To isolate PBLs, mononuclear cells were obtained from fresh
human peripheral blood by centrifugation on Ficoll-Paque den-
sity gradients, washed with PBS, and resuspended in RPMI 1640
containing 10% heat-inactivated FCS. Monocytes were depleted
by culture dish adherence after overnight incubation. Nonadher-
ent cells (lymphocytes) were washed with PBS and collected.
Lymphocyte preparations were typically 69–74% CD3
 
 
 
, 25–28%
CD19
 
 
 
, and 
 
 
 
0.4% CD14
 
  
 
(12).
The human fibrosarcoma HT1080 cell line, obtained from the
German Collection of Microorganisms and Cell Cultures, as well
as the murine fibroblasts L929 and L929-Fas, stably transfected
with human Fas cDNA (provided by P.H. Krammer, DKFZ,
Heidelberg, Germany; reference 27), were grown in DMEM
culture medium supplemented with 10% heat-inactivated FCS, 2
mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 24 
 
 
 
g/ml gentamicin
(12). L929-Fas cells were grown in the presence of 500 
 
 
 
g/ml
hygromycin. A PCR-generated DNA fragment encoding a 57C
terminally truncated Fas version (Fas
 
 
 
57C) was prepared using
the plasmid pKEX-Fas (28) as a template, cloned into the eukary-
otic expression vector pKEX-2-XR, and the sequence was veri-
fied by double-strand DNA sequencing. Transfection of L929
cells with pKEX-Fas
 
 
 
57C plasmid was performed using Lipofec-
tin reagent (Life Technologies) and hygromycin for clone selec-
tion. As a control, transfection was also performed with empty
pKEX-2-XR plasmid.
 
Human and Rat Hepatocytes.
 
Human hepatocytes were ob-
tained from small surgical liver biopsies by a two-step collagenase
perfusion method (29). Rat hepatocytes were prepared from 20-
d-old fetal rat livers by a nonperfusion collagenase dispersion
method (30).
 
Immunofluorescence Flow Cytometry.
 
Cell surface expression of
death receptors was analyzed by immunofluorescence flow cy-
tometry in 4 
 
  
 
10
 
5 
 
cells as described previously (12, 31) in a Bec-
ton Dickinson FACSCalibur™ flow cytometer using anti-Fas
SM1/1 mAb (Bender MedSystems) and specific antibodies against
TNFR1 and TRAIL-R2/DR5 (Qbiogene, Oncogene Research
Products, and Santa Cruz Biotechnology, Inc.). P3X63 myeloma
culture supernatant, provided by F. Sanchez-Madrid (Hospital de
La Princesa, Madrid, Spain), was used as a negative control.
 
Apoptosis Assay.
 
Quantitation of apoptotic cells was deter-
mined by flow cytometry as the percentage of cells in the sub-G
 
1
 
region (hypodiploidy) in cell cycle analysis as described previ-
ously (12). Death receptor–mediated apoptosis was induced with
rhTRAIL or rhFasL (Qbiogene), active in human and murine
systems, murine TNF-
 
  
 
(provided by M. Modolell, Max-Planck-
Institut für Immunbiologie, Freiburg, Germany), rhTNF-
 
  
 
(Qbio-
gene), and cytotoxic anti-Fas CH-11 mAb (Upstate Biotechnol-
ogy; reference 12).
 
ET-18-OCH
 
3 
 
Uptake.
 
Drug uptake was measured as de-
scribed previously (5) after incubating 10
 
6
 
/ml cells with 10 
 
 
 
M
ET-18-OCH
 
3 
 
plus 0.05 
 
 
 
Ci/ml [
 
3
 
H]ET-18-OCH
 
3 
 
for 6 h, and
subsequent exhaustive washing (five times) with 1% BSA-PBS.
ET-18-OCH
 
3 
 
stock solutions (INKEYSA) were prepared as de-
scribed previously (5). [
 
3
 
H]ET-18-OCH
 
3 
 
(specific activity, 42
Ci/mmol) was synthesized by tritiation of the 9-octadecenyl de-
rivative (Amersham Buchler).
 
Microinjection Assays and Detection of DNA Fragmentation by
TdT-mediated dUTP Nick-End Labeling (TUNEL).
 
Cells were
grown on 24-mm diameter poly-
 
l
 
-lysine–coated glass coverslips
and microinjected with glass microelectrodes (150–200 M
 
 
 
)
filled with 1.2% rhodamine-conjugated dextran (Molecular Probes)
in 1 M KCl as a marker or with rhodamine-conjugated dextran
plus 190 
 
 
 
M ET-18-OCH
 
3
 
, which renders final intracellular
drug concentrations comparable to the normally used doses (12).
Cells were microinjected using a hydraulic 3D micromanipulator
(Narishige) under visual control (40-kPa for 0.1–1 s; Diaphot mi- 
Gajate et al.
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croscope; Nikon; reference 12). Cells were then incubated in
10% FCS-DMEM for 6 h, fixed with 4% formaldehyde, perme-
abilized with 0.2% Triton X-100, and analyzed for DNA frag-
mentation in situ by the TUNEL technique using the Fluorescein
Apoptosis Detection System kit (Promega) according to the man-
ufacturer’s instructions. Fluorescence of rhodamine and fluores-
cein was examined with a laser scan confocal microscope (LSM 510;
Carl Zeiss MicroImaging, Inc.). Rhodamine stains red through-
out the cytoplasm of all the microinjected cells, whereas fluores-
cein-12-dUTP is incorporated at the 3
 
 
 
-OH ends of fragmented
DNA, resulting in localized green fluorescence within the nu-
cleus of apoptotic cells.
 
Confocal Microscopy.
 
Untreated and drug-treated cells were
settled onto poly-
 
l
 
-lysine–coated slides and analyzed with a Zeiss
LSM 510 laser scan confocal microscope for raft and protein visu-
alization as described previously (14). Colocalization assays were
analyzed by excitation of the corresponding fluorochromes in the
same section of permeabilized or nonpermeabilized samples.
Negative controls, lacking the primary antibody or using an irrel-
evant antibody, showed no staining.
 
Lipid Raft Isolation and Western Blotting.
 
Lipid rafts were iso-
lated from 7 
 
  
 
10
 
7 
 
cells by nonionic detergent lysis and centrifuga-
tion on discontinuous sucrose gradients as described previously (14,
32). 1-ml fractions were collected from the top of the gradient and
20 
 
 
 
l of each fraction was subjected to SDS-PAGE, immunoblot-
ting, and enhanced chemiluminescence detection. Location of
G
 
M1
 
-containing lipid rafts was determined using cholera toxin
(CTx) B subunit conjugated to horseradish peroxidase (Sigma-
Aldrich) as described previously (32). Proteins were identified us-
ing the following specific antibodies: anti–48-kD Fas (C-20) and
anti–46-kD JNK1 (C-17) rabbit polyclonal antibodies, and anti–
23-kD Bid (N-19) and anti–45-kD DR5 (N-19) goat polyclonal
antibodies (Santa Cruz Biotechnology, Inc.); anti–29-kD FADD mAb
(clone-1; BD Transduction Laboratories); anti–60-kD TNFR1
(H398) mAb (Qbiogene); and anti–45-kD DR5 (Ab-1) rabbit
polyclonal antibody, anti–55-kD procaspase-8 (Ab-3), and anti–
58-kD procaspase-10 (Ab-2) mAb (Oncogene Research Products).
 
Sphingomyelin and Ceramide Measurement.
 
Cellular lipid pools
were metabolically radiolabeled by culturing cells for 3 d in the
presence of 0.5 
 
 
 
Ci/ml [methyl-
 
3
 
H]choline or L-[
 
14
 
C]serine, and
the radiolabeled pools of sphingomyelin and ceramide were
analyzed by thin layer chromatography (TLC) and scintillation
counting after the distinct cellular treatments (33). [
 
3
 
H]choline-
labeled extracts were separated by TLC using chloroform/metha-
nol/25% NH
 
4
 
OH (60:30:5) as the solvent system, allowing sepa-
ration of sphingomyelin. [
 
3
 
H]serine-labeled extracts were subjected
to an alkaline hydrolysis procedure. Lipids were dissolved into
chloroform/methanol (1:1) containing 0.1 M NaOH. After an
incubation of 1 h at 37
 
 
 
C, the remaining lipids were reextracted
and subdivided on two TLC plates, which were developed in
chloroform/acetic acid (9:1), separating ceramide, or chloro-
form/methanol/25% NH
 
4
 
OH (60:30:5), separating sphingomye-
lin. Radiolabeled lipids were identified by autoradiography as
well as by the use of unlabeled standards, scraped from the plates,
and counted for radioactivity.
Ceramide was also quantified by the diacylglycerol kinase assay as
described previously (33) using 5 
 
  
 
10
 
5 
 
cells and 300 
 
 
 
Ci/ml
[
 
 
 
-
 
32
 
P]ATP in each experimental point. Radiolabeled lipids were vi-
sualized by TLC and autoradiography, and the ceramide-1-phosphate
spots were scraped from the plates and counted for radioactivity.
 
SMase Activities.
 
Neutral and acidic SMase was assayed in the
absence of serum using [choline-methyl-
 
14
 
C]-sphingomyelin as
described previously (34). In brief, volumes were adjusted to 125
 
 
 
l (10
 
5 
 
Jurkat cells) and reactions were started by adding 125 
 
 
 
l
of substrate solution. For the measurement of acidic SMase activ-
ity, the substrate solution consisted of [methyl-choline-
 
14
 
C]-
sphingomyelin (10
 
5 
 
dpm/assay) and 0.1% (wt/vol) Triton X-100
in 250 mM sodium acetate buffer, pH 5.0, containing 10 mM
EDTA. For neutral SMase activity assays, the substrate solution
consisted of [methyl-choline-
 
14
 
C]-sphingomyelin (10
 
5 
 
dpm/assay)
and 0.1% (wt/vol) Triton X-100 in 250 mM Tris HCl buffer, pH
7.4, containing 10 mM dithiothreitol and 10 mM MgCl
 
2
 
. After
2 h of incubation at 37
 
 
 
C, reactions were terminated by extract-
ing the lipids by subsequent addition of methanol/chloroform/
H
 
2
 
O (100:100:50), and the sphingomyelin degradation product
[
 
14
 
C]phosphorylcholine was quantified in the aqueous upper phase
by liquid scintillation counting.
 
PTE-ET-18-OCH
 
3 
 
Synthesis and Uptake.
 
The fluorescent
analogue PTE-ET-18-OCH
 
3 
 
was synthesized through cross-cou-
pling between 1-bromopolyene and 1,3-glycerol acetal with a
terminal acetylene group, followed by partial reduction (unpub-
lished data). Cells (2.5 
 
  
 
10
 
5 
 
cells/ml) were treated with 20 
 
 
 
M
PTE-ET-18-OCH
 
3 
 
for 7 h in 10% FCS-RPMI 1640, washed
three times with 1% BSA-PBS, and the incorporated fluorescence
was measured with a microplate fluorometer (TECAN). 2 
 
  
 
10
 
5
 
PTE-ET-18-OCH
 
3
 
–treated cells were settled onto poly-
 
l
 
-
lysine–coated slides, fixed in 4% formaldehyde for 25 min at
room temperature, and analyzed using a fluorescence microscope
(Axioplan 2; Carl Zeiss MicroImaging, Inc.) and a digital camera
(ORCA-ER-1394; Hamamatsu).
 
Results
 
ET-18-OCH
 
3
 
–induced Apoptosis Involves Drug Uptake and
Intracellular Activation of Fas, but Is Independent of TNF and
TRAIL Functional Receptors.
 
Our previous reports indi-
cated that Fas activation was involved in ET-18-OCH
 
3
 
–
mediated apoptosis (12, 14). To gain further insight and to
discern whether additional death receptors could be
involved in ET-18-OCH3–induced apoptosis, we used
mouse fibrosarcoma Fas-deficient L929 cells and generated
stable transfectants with the pKEX-2-XR expression vector
containing human full Fas (L929-Fas) or a truncated version
of human Fas (L929-Fas 57C), lacking the 57 COOH-ter-
minal amino acids (amino acids 279–335) that included part
of the Fas cytoplasmic death domain (35). L929-Fas and
L929-Fas 57C cells expressed high levels of human Fas
protein on their cell surface (Fig. 1 A). L929, L929-Fas, and
L929-Fas 57C were sensitive to TNF-  and TRAIL (Fig.
1 B), indicating the functional presence of their corre-
sponding receptors. rhFasL or the agonistic cytotoxic CH-
11 anti-Fas mAb induced apoptosis in L929-Fas cells, but
not in L929-Fas 57C cells (Fig. 1 B). Parental and trans-
fected L929 cells hardly incorporated ET-18-OCH3 ( 0.2
nmol/106  cells after 6 h of incubation with 10 nmol
[3H]ET-18-OCH3) and were resistant to ET-18-OCH3 in-
cubation ( 1% apoptosis after a 2-d treatment with 10  M
ET-18-OCH3), indicating that Fas has no role in the incor-
poration of the ether lipid. Microinjection of ET-18-
OCH3 into L929-Fas cells induced a potent apoptotic re-
sponse, but not in L929 or L929-Fas 57C cells (Fig. 1 C).
L929 cells transfected with empty pKEX-2-XR expression
vector behaved as parental L929 cells (not depicted). TheseSelective Fas Activation in Tumor Cells 356
results demonstrate that ET-18-OCH3 must be inside the
cell to promote Fas-mediated apoptosis and suggest that the
proapoptotic action of the ether lipid is mediated by the in-
tracellular domain of Fas. These data also demonstrate that
the presence of Fas in the target cell, independently of other
TNF- – or TRAIL-activated death receptors, is essential
for ET-18-OCH3–mediated apoptosis.
ET-18-OCH3 Induces Recruitment and Clustering of Fas and
Downstream Signaling Molecules into Membrane Rafts. Hu-
man T lymphoid leukemic Jurkat cells take up high
amounts of ET-18-OCH3 (3.1   0.4 nmol/106 cells after
6 h of incubation with 10 nmol [3H]ET-18-OCH3; n   3),
resulting in Fas translocation and clustering into membrane
rafts followed by apoptosis (12, 14). Jurkat cells express a
number of functional death receptors, including Fas,
TNFR1, and TRAIL-R2/DR5 (12, 36, 37), but not
TRAIL-R1/DR4 (38). We asked whether the intracellu-
lar-driven engagement and translocation of Fas into mem-
brane rafts by ET-18-OCH3 was specific for Fas or could
involve additional death receptors. We found that ET-18-
OCH3 induced aggregation of Fas, but not of TNFR1 or
DR5, into “caps” on one pole of the cell as evidenced by
confocal microscopy (Fig. 2 and not depicted). These Fas
clusters colocalized with membrane rafts (Fig. 2) as assessed
by the raft marker FITC-CTx B subunit that binds ganglio-
side GM1 (39), mainly found in rafts (40). ET-18-OCH3–
induced clustering of lipid rafts was detectable after only 15–
30 min of 10  M ET-18-OCH3 incubation, whereas re-
cruitment of Fas into the raft clusters was observed after a
6-h treatment, preceding apoptosis that was detectable after
a 9-h treatment. Translocation of Fas into rafts was further
confirmed by isolation of membrane rafts in both untreated
and ET-18-OCH3–treated Jurkat cells in sucrose gradients
(Fig. 3). Lipid rafts were isolated based on their insolubility
in Triton X-100 detergent and buoyant density on sucrose
density gradients (41). Thus, Jurkat cells were lysed in a
1% Triton X-100 lysis buffer at 4 C and fractionated by
discontinuous sucrose gradient centrifugation (14, 32).
The distinct fractions from the gradient were analyzed by
SDS-PAGE and Western blotting. The position of the
membrane rafts in the sucrose gradient was determined by
the presence of the ganglioside GM1, detected using the GM1-
specific ligand CTx B subunit (Fig. 3). GM1 was enriched in
the upper part of the sucrose gradient (fractions 3–6), with a
secondary localization at the bottom of the gradient (frac-
tions 9–12), indicating a separation of lipid rafts (fractions
3–6) from the Triton X-100-soluble membranes (Fig. 3).
Using a specific anti-Fas mAb, we found that Fas was lo-
cated in the soluble fractions (fractions 9–12) of the sucrose
gradient and not in the detergent-insoluble lipid raft region
in untreated Jurkat cells, indicating that Fas is excluded from
the lipid rafts in untreated Jurkat cells (Fig. 3). However,
ET-18-OCH3 treatment induced the recruitment of Fas
into the lipid raft region (fractions 4–6) of the sucrose gradi-
Figure 1. Intracellular Fas activation in ET-18-OCH3–mediated apoptosis. L929, L929-Fas, and L929-Fas 57C cells were assayed by flow cytometry
for their respective cell surface content of Fas using anti-Fas SM1/1 mAb (A), and for the ability of 100 U/ml murine TNF-  (TNF), 50 ng/ml
rhTRAIL, 100 ng/ml rhFasL, and 50 ng/ml cytotoxic anti-Fas CH-11 mAb to induce apoptosis after a 24-h incubation in the presence of 500 ng/ml
actinomycin D (B). Untreated control cells (Control) were run in parallel. Data shown are means   SD of three independent determinations. (C) Apoptosis was
determined by TUNEL analysis in L929, L929-Fas, and L929-Fas 57C cells after microinjection of rhodamine-labeled dextran alone (Control), used to
visualize the microinjected cells by red fluorescence, or in combination with ET-18-OCH3 (ET-18-OCH3). Microinjected cells are identified by cyto-
plasmic red staining, and apoptotic nuclei are visualized by the TUNEL reaction in green. Images shown are representative of four independent experi-
ments. Bar, 10  m.Gajate et al. 357
ent (Fig. 3). These data showed a rather remarkable specific-
ity for Fas in the action of ET-18-OCH3, as two additional
major death receptors, namely TNFR1 and DR5, were not
mobilized to rafts. We also found that FADD and pro-
caspase-8, major components of the DISC (42), were re-
cruited to the Fas-containing clustered rafts after ET-18-
OCH3 treatment (Fig. 3). This colocalization was further
confirmed by confocal microscopy (not depicted). Pro-
caspase-10 was also recruited into rafts to a higher level than
procaspase-8 (Fig. 3). However, the active caspase-10 and
caspase-8 cleavage forms localized mostly in nonraft frac-
tions (Fig. 3). Surprisingly, we found that JNK and Bid
were also recruited into the lipid raft region upon ET-18-
OCH3 treatment (Fig. 3). This is of interest as JNK and mi-
tochondrial signaling have been involved in ET-18-OCH3–
mediated apoptosis (7–11), and Bid has been shown to act as
a bridge between Fas signaling and mitochodria (43, 44).
Disruption of rafts after a 30-min pretreatment with 2.5
mg/ml methyl- -cyclodextrin prevented ET-18-OCH3–
induced apoptosis (51.5   5.2 and 6.8   0.9% apoptosis
after a 24-h incubation with 10  M ET-18-OCH3 in un-
treated or methyl- -cyclodextrin–treated Jurkat cells, re-
spectively; n   3), Fas aggregation, and the translocation of
the apoptotic signaling molecules (not depicted). Thus, ET-
18-OCH3–induced clustering of Fas-containing rafts re-
cruits and concentrates to the cytoplasmic side of the plasma
membrane a number of molecules required to mount an ef-
ficient Fas-dependent apoptotic response, forming clusters
of rafts enriched in apoptotic signaling molecules.
Although Fas and the components of the DISC have
been reported to be recruited to lipid rafts after Fas ligation
in mouse thymocytes and human T cell lines (16, 17), a re-
cent report has shown that FasL induces cell death in hu-
man fibrosarcoma HT1080 cells without translocation of
Fas to lipid rafts (45). This suggests that translocation of Fas
to lipid rafts is cell type dependent. Next, we investigated
whether ET-18-OCH3 could induce apoptosis as well as
Fas translocation to lipid rafts in HT1080 cells that were re-
luctant to mobilize Fas to rafts. We found that HT1080
cells were resistant to the apoptotic action of ET-18-OCH3
( 3% apoptosis after a 2-d treatment with 10  M ET-18-
OCH3), and no raft or Fas clustering was observed in ET-
18-OCH3–treated HT1080 cells (not depicted). On the
other hand, treatment of HT1080 with the agonistic CH-
11 mAb induced apoptosis (39.4   4.8% apoptosis after a
48-h incubation with 50 ng/ml CH-11; n   3), but no raft
or Fas clustering was detected (not depicted), in agreement
with previous observations (45). Thus, these data further
support the notion that ET-18-OCH3–induced apoptosis is
mediated by Fas translocation to lipid rafts.
ET-18-OCH3–induced Fas and Raft Clustering Do Not Re-
quire Protein Synthesis. Next, we analyzed whether ET-
18-OCH3 could induce a marked up-regulation of Fas on
the cell surface, resulting in a high density of Fas and subse-
quent spontaneous clustering of the receptor. However,
ET-18-OCH3 did not induce any increase on the Fas cell
surface expression (Fig. 4 A), and cycloheximide pretreat-
ment, at protein synthesis inhibitory concentrations (not
Figure 2. ET-18-OCH3–induced cluster-
ing of Fas, but not of TNFR1, in human
leukemic cells. Jurkat cells were either un-
treated (Control) or treated with 10  M
ET-18-OCH3  for 6 h, and then stained
with FITC-CTx B subunit to identify rafts
(green fluorescence) and with specific anti-
bodies followed by CY3-conjugated anti-
bodies (red fluorescence) to identify Fas (A)
or TNFR1 (B). Areas of colocalization be-
tween membrane rafts and the indicated
proteins in the merge panels are yellow.
Images  shown are representative of three
independent experiments. Bar, 10  m.Selective Fas Activation in Tumor Cells 358
depicted), did not affect raft and Fas coclustering after ether
lipid incubation (Fig. 4 B). These results demonstrate that
ET-18-OCH3–induced raft and Fas clustering do not de-
pend on protein synthesis, and thereby ET-18-OCH3 in-
duces translocation and clustering of Fas in lipid rafts from
the pool of Fas already present in the tumor cell. This is in
agreement with our previous observations that ET-18-
OCH3–induced apoptosis does not depend on protein syn-
thesis (10), and that ET-18-OCH3 did not induce any
change in the expression of fas mRNA level (12).
Raft Clustering in the Absence of Fas Does Not Induce Apop-
tosis in ET-18-OCH3–treated Cells. Because rafts were
necessary for both Fas cell surface aggregation and ET-18-
OCH3–induced apoptosis, and clustering of rafts was
rapidly induced after ET-18-OCH3 addition, we asked
whether raft clustering was sufficient to trigger apoptosis.
Figure 3. Recruitment of Fas and downstream signal-
ing molecules into membrane rafts after ET-18-OCH3
treatment. Untreated Jurkat cells (Control) and Jurkat
cells treated with 10  M ET-18-OCH3 (ET-18-OCH3)
for 6 h were lysed in 1% Triton X-100 and subjected
to discontinuous sucrose density gradient centrifuga-
tion. Individual fractions were subjected to SDS-PAGE
and Western blotting. Location of GM1-containing rafts
(fractions 3–6) was determined using CTx B subunit
conjugated to horseradish peroxidase. Location of the
indicated receptors and signaling proteins were exam-
ined using specific antibodies. Active p18 caspase-8 and
p23 caspase-10 cleavage forms are indicated. Represen-
tative blots of three separate experiments are shown.
Figure 4. Clustering of Fas is independent of protein synthesis. (A) Cell surface expression of Fas was determined by immunofluorescence flow cytome-
try in untreated Jurkat cells (Control) and cells treated with 10  M ET-18-OCH3 for 6 h. Data shown are means   SD of three independent experiments.
(B) Jurkat cells, preincubated with 5  M cycloheximide (CHX) for 1 h and then treated with 10  M ET-18-OCH3 for 6 h, were stained with FITC-CTx
B subunit (green fluorescence for rafts) and anti-Fas mAb, followed by CY3-conjugated anti–mouse antibody (red fluorescence for Fas). Areas of colocal-
ization between membrane rafts and Fas in the merge panels are yellow. Images shown are representative of three independent experiments. Bar, 10  m.Gajate et al. 359
We generated a subline from the leukemic Jurkat cell line
that lacked Fas cell surface expression after protracted cul-
tures ( 10 mo) of parental cells. Fas-deficient Jurkat cells
preserved the expression of TNFR1 and DR5 at similar
levels as the parental Jurkat cells, but lacked Fas (Fig. 5 A),
resulting in CH-11–, rhFasL-, and ET-18-OCH3–resistant
cells (Fig. 5 B). However, Fas-deficient Jurkat cells under-
went apoptosis after TNF-  or TRAIL incubation (not de-
picted). Interestingly, ET-18-OCH3 promoted clustering
of rafts in Fas-deficient Jurkat cells in a similar way as in the
parental Jurkat cells (Fig. 5 C), indicating that clustering of
rafts was not sufficient to trigger an apoptotic response.
These data further indicate that Fas is a major mediator in
ET-18-OCH3 proapoptotic action and that the abilities of
the ether lipid in promoting raft clustering and apoptosis
can be dissociated.
ET-18-OCH3 Does Not Activate SMase. Because SMase-
released ceramide has been involved in Fas aggregation and
killing (15, 24), we analyzed its putative involvement in
ET-18-OCH3–induced apoptosis. Serine is a metabolic
precursor for the biosynthesis of all sphingolipids, including
ceramide and sphingomyelin. Choline forms part of the
headgroup of both sphingomyelin and phosphatidylcho-
line. By growing cells in the presence of [3H]choline or
[14C]serine, all mentioned lipids become radiolabeled. This
allows sensitive detection of any change in the cellular lev-
els of these lipids. As shown in Fig. 6 A, [3H]choline-
labeled sphingomyelin pools were not affected in ET-18-
OCH3–treated Jurkat cells. ET-18-OCH3 did not affect
[3H]serine-labeled sphingomyelin or ceramide cell levels
(Fig. 6, B and C). In addition, ET-18-OCH3 did not in-
duce significant elevations in endogenous ceramide levels
determined through the diacylglycerol kinase assay that al-
lows mass measurement of ceramide (Fig. 6 D). Further-
more, we did not find any significant change in neutral and
acidic SMase activities after ET-18-OCH3 treatment using
[14C]sphingomyelin as substrate in time course experiments
that included 1-, 5-, 15-, 30-, and 60-min time points
(not depicted). Moreover, ET-18-OCH3 failed to activate
SMase in human leukemic HL-60 and U937 cells (not de-
picted), which undergo ET-18-OCH3–mediated apoptosis
(10, 14). These data suggest that SMase activation is not re-
quired in ET-18-OCH3–induced apoptosis.
ET-18-OCH3 Accumulates in Membrane Rafts and Colocal-
izes with Fas Clusters. Next, we asked whether ET-18-
OCH3 itself could colocalize with Fas in membrane rafts.
We synthesized a novel ET-18-OCH3 fluorescent analogue
able to preserve the selectivity for cancer cells of the paren-
tal drug. Because the sn-1 position of the ET-18-OCH3
molecule can hold some modifications preserving drug bio-
activity (5), we synthesized an ET-18-OCH3 analogue re-
placing the sn-1 C18 aliphatic chain of ET-18-OCH3 by a
lipophilic fluorescent group of similar length containing
a conjugated  -phenyltetraene group (all-[E]-1-O-[15 -
phenylpentadeca-8 ,10 ,12 ,14 -tetraenyl]-2-O-methyl-rac-
glycero-3-phosphocholine, PTE-ET-18-OCH3, mol wt,
550.33) that shows maximum absorption bands at 334,
350, and 368 nm, and emission at 442 and 467 nm. This
fluorescent analogue induced apoptosis in T lymphoid leu-
kemia Jurkat cells (Fig. 7 A), whereas it spared normal hu-
Figure 5. Clustering of Fas-deficient rafts is not sufficient for apoptosis.
(A) Cell surface expression of Fas, TNFR1, and DR5 in Jurkat (JK) and
Fas-deficient Jurkat cells was determined by flow cytometry. Percent of
positive cells for each death receptor was estimated using the P3X63
(X63) myeloma culture supernatant as negative control. (B) Induction of
apoptosis in Jurkat (JK) and Fas-deficient Jurkat cells was determined by
flow cytometry after a 24-h incubation with 50 ng/ml cytotoxic anti-Fas
CH-11 mAb, 100 ng/ml rhFasL (FasL), or 10  M ET-18-OCH3 (ET).
Untreated control cells (C) were run in parallel. Data shown are means  
SD of three independent experiments. (C) Fas-deficient Jurkat cells were
untreated (Control) or incubated with 10  M ET-18-OCH3 (ET-18-
OCH3) for 6 h, and then stained with FITC-CTx B subunit and analyzed
by confocal microscopy to visualize membrane rafts. Images shown are
representative of three independent experiments. Bar, 10  m.Selective Fas Activation in Tumor Cells 360
man PBLs in a similar way to ET-18-OCH3 ( 2% apopto-
sis in 10–30  M ET-18-OCH3– or PTE-ET-18-OCH3–
treated resting PBLs for 24 h). Incubation of human leuke-
mic HL-60 and Jurkat cells with this fluorescent analogue,
followed by exhaustive washing with a BSA-containing
buffer to eliminate the loosely cell surface–bound ether
lipid, led to an accumulation of the fluorescent analogue
into well-defined dense patches, whereas a faint labeling
was hardly detected in normal PBLs (Fig. 7 B). Incorpora-
tion of the fluorescent ET-18-OCH3 analogue was blocked
by adding the parental drug ET-18-OCH3 (not depicted).
The selective uptake of the ether lipid in tumor cells was
further corroborated by quantitative fluorescence spectros-
copy measurements (Fig. 7 C). Thus, the new fluorescent
compound behaves as a reliable active fluorescent analogue
of ET-18-OCH3 that allows us to visualize the location of
ET-18-OCH3 in situ. We found that fluorescent PTE-ET-
18-OCH3 colocalized with Fas-containing membrane rafts
into caps on one or two poles of the Jurkat cells (Fig. 8).
Time course experiments showed that ET-18-OCH3 rap-
idly accumulated in lipid raft clusters after 15–30 min of in-
cubation (not depicted). Interestingly, PTE-ET-18-OCH3
remained accumulated in Fas-containing membrane clus-
ters even after 15 h of treatment in Jurkat cells, when cells
undergo apoptosis (not depicted), indicating that ET-18-
OCH3 remained plasma membrane bound.
ET-18-OCH3 Spares Normal Human and Rat Hepatocytes.
Treatment of mice with an anti-Fas monoclonal agonistic
antibody induces massive apoptosis of hepatocytes, which
express abundant Fas, leading to fulminant hepatic failure
and to the death of animals within a few hours (46). These
hepatic effects prevent clinical use of exogenous Fas activa-
tion. Unlike agonistic cytotoxic anti-Fas CH-11 antibody
that induced apoptosis in human hepatocytes, ET-18-
OCH3 was not cytotoxic (Fig. 9). Rat hepatocytes were
also spared ( 3% apoptosis) after a 24-h treatment with ei-
ther 10 or 20  M ET-18-OCH3. We found that neither
normal human nor rat hepatocytes incorporated significant
amounts of ET-18-OCH3 ( 0.2 nmol/106 cells after 6 h of
incubation with 10 nmol [3H]ET-18-OCH3; n   3), and
therefore intracellular Fas activation was prevented.
Discussion
Here we describe a novel mechanism of action for an an-
titumor drug that involves: (a) drug insertion into lipid rafts
promoting their clustering, (b) intracellular activation of Fas
through its translocation and clustering into membrane raft
caps on one pole of the cell, and (c) translocation of down-
stream Fas signaling molecules into Fas caps forming clusters
of rafts enriched in apoptotic signaling molecules. This
unique mode of action of the antitumor ether lipid ET-18-
OCH3 (Edelfosine) illustrates the first use of raft-dependent
and intracellular activated Fas-mediated killing in cancer
chemotherapy, representing a new way to target tumor cells
that can be of interest as a new framework in designing
novel antitumor drugs. Evidence for the intracellular activa-
tion of the death receptor Fas by ET-18-OCH3 is manifold:
(a) ET-18-OCH3 must be incorporated into the cells, likely
into the cytoplasmic leaflet of the plasma membrane, to ac-
tivate Fas and induce apoptosis; (b) a partial deletion of the
intracellular domain of Fas blocks ET-18-OCH3–mediated
apoptosis; (c) cells sensitive to ET-18-OCH3 become resis-
tant when Fas is lost; and (d) Fas-deficient cells are resistant
to ET-18-OCH3, but become sensitive upon enforced Fas
expression. Furthermore, our data indicate that ET-18-
OCH3 activates and translocates Fas into clustered mem-
brane rafts, whereas other major death receptors, such as
TNFR1 and TRAIL-R2/DR5 receptors, are not affected,
Figure 6. Lack of SMase activation and ceramide generation by ET-18-
OCH3. Jurkat cells were labeled with [methyl-3H]choline and L-[14C]serine,
and then treated with 10  M ET-18-OCH3 for the indicated time points.
The incorporation of [methyl-3H]choline and L-[14C]serine into sphingo-
myelin (SM) (A and B) and the incorporation of L-[14C]serine into ceramide
(C) was determined as a percentage to untreated control cells. Ceramide
content was also calculated by the diacylglycerol (DAG) kinase assay (D).
Jurkat cells treated with 500 U/ml TNF-  (TNF) for 30 min or with 0.3
U/ml Staphylococcus aureus SMase for 1 h were used as positive controls.
Data shown are means   SD of three independent determinations.Gajate et al. 361
suggesting a specificity for Fas. Thus, it is suggested that Fas
is engaged by ET-18-OCH3, although whether the ether
lipid interacts directly with Fas or activates the receptor
through a more indirect way remains to be elucidated.
The synthesis of the first bioactive ET-18-OCH3 fluo-
rescent analogue allowed us to visualize the location of the
ether lipid in membrane rafts, in agreement with a recent
report using [3H]ET-18-OCH3 (47). Here we found that
fluorescent PTE-ET-18-OCH3 colocalized with Fas and
membrane rafts, suggesting that ET-18-OCH3 could inter-
act with both rafts and Fas intracellularly, and then ET-18-
OCH3 self-aggregates translocating Fas into the lipid rafts.
Figure 7. Selective incorporation of the fluorescent analogue PTE-ET-18-OCH3 in
human leukemic cells. Human leukemic Jurkat cells were incubated with the indicated
concentrations of ET-18-OCH3 or PTE-ET-18-OCH3 for 24 h and apoptosis was mea-
sured by flow cytometry (A). Normal PBLs and leukemic HL-60 and Jurkat cells (JK)
were treated with 20  M PTE-ET-18-OCH3 for 7 h, washed with 1% BSA-PBS, and
fluorescent drug uptake was analyzed by fluorescence microscopy (blue fluorescence) (B)
or by fluorescence quantitation (C). Data shown are means   SD of three independent
determinations.
Figure 8. Accumulation of the fluorescent ana-
logue PTE-ET-18-OCH3 in Fas-enriched raft caps
in leukemic cells. Jurkat cells were incubated with
20  M PTE-ET-18-OCH3 (blue fluorescence) for
6 h, and then its colocalization with membrane rafts
(A) and Fas (B) was examined using FITC-CTx B
subunit (green fluorescence for rafts) and anti-Fas
SM1/1 mAb, followed by CY3-conjugated anti–
mouse antibody (red fluorescence for Fas). Images
shown are representative of four independent ex-
periments. Bar, 10  m.Selective Fas Activation in Tumor Cells 362
It could be argued that the presence of an additional lipid,
ET-18-OCH3, might affect isolation of rafts through their
resistance to solubilization by nonionic Triton X-100 at
4 C. This latter is the most widely used approach for raft
isolation, despite its limitations and the fact that the highly
asymmetric nature of the bilayer likely could lead to anom-
alous processes during detergent solubilization (41, 48).
However, the differential localization of some proteins be-
tween raft-enriched and nonraft fractions in untreated ver-
sus ET-18-OCH3–treated cells (Fig. 3), the agreement be-
tween confocal and biochemical data on Fas and TNFR1
localization after ET-18-OCH3 treatment (compare Figs. 2
and 3), and the fact that ET-18-OCH3 is expected to be in
much lower amounts than endogenous raft lipids, suggest
that this method is reliable for the analysis of protein trans-
location to lipid rafts after ether lipid treatment and that
ET-18-OCH3 does not cause significant changes in the iso-
lation behavior of rafts.
An interesting finding from this work is that ET-18-
OCH3 must be inside the cell, likely the inner leaflet of the
plasma membrane, to alter rafts that are supposed to be
mainly present in the outer leaflet of the cell membrane.
The behavior of rafts in the cytoplasmic leaflet of the bi-
layer is an important, unresolved issue, but it is suggested
that raft-like structures are also present in the inner leaflet
and that rafts in the two leaflets are coupled (41, 48). The
difference in length of the acyl chains of sphingolipids can
allow them to interdigitate with the lipids in the inner leaf-
let (18, 49) forming putative inner leaflet rafts. Confocal
imaging and fluorescence spectroscopy have shown a cor-
relation between like phases in the two leaflets of model
membranes containing two phospholipid species (50). In
this regard, it could be envisaged that the insertion of ET-
18-OCH3 into these putative inner leaflet rafts might in-
duce local and transient changes in the interactions with
their outer leaflet counterparts.
The clinical usefulness of exogenous activation of Fas as
well as of the other major death receptors, namely TNF
and TRAIL receptors, by their respective ligands or ago-
nists has been hampered by toxic side effects. Systemic ad-
ministration of TNF causes a severe inflammatory response
syndrome that resembles septic shock (51), administration
of agonistic antibody to Fas in mice is lethal because of
liver failure through massive hepatocyte apoptosis (46), and
TRAIL induces apoptosis of human hepatocytes (52).
Here, we found that both human and rat hepatocytes are
spared after ET-18-OCH3 treatment. Our present and pre-
vious findings (5, 12) show that Fas engagement by ET-
18-OCH3  selectively triggers apoptosis in tumor cells,
whereas normal cells are spared. In this regard, additional
normal cells, such as resting PBLs, neutrophils, normal
bone marrow human hematopoietic progenitors, human
umbilical vein endothelial cells, and bovine aortic endo-
thelial cells, are resistant to treatment with ET-18-OCH3
(5, 8, 12). This is due to the fact that ET-18-OCH3 does
not activate Fas extracellularly, but from inside the cell in a
FasL-independent manner, and the ether lipid is taken up
by tumor cells but not by normal cells. The molecular ex-
planation for the selective uptake of ET-18-OCH3 by tu-
mor cells, leading to drug selectivity for tumors, remains to
be elucidated. ET-18-OCH3 contains just one long alkyl
chain as well as a polar head group, conferring the mole-
cule its amphiphilic properties, which implies that the lipid
is water soluble and can be administered orally (3).
The particular amphiphilic molecular structure of ET-18-
OCH3 suggests that this ether phospholipid readily inserts
into the outer leaflet of the plasma membrane, but due to
its water-soluble head group, the lipid will not flip-flop
spontaneously across the plasma membrane. Indirect evi-
dence suggests that a protein structure could be involved
in the ether lipid uptake. Suramin, a broad specificity
membrane–impermeable inhibitor of ligand receptor inter-
actions (53), inhibits both ET-18-OCH3 uptake and ET-
18-OCH3–induced apoptosis in leukemic cells (5). A pho-
toactivatable analogue of ET-18-OCH3 is able to interact
with two proteins of MCF-7 breast cancer cells (54).
Lem3p (ligand effect modulator 3 protein; reference 55)
and LdMT (Leishmania donovani putative Miltefosine Trans-
porter; reference 56) have been recently found to be re-
quired for the uptake of alkylphosphocholine drugs, in-
cluding ET-18-OCH3, into Saccharomyces cerevisiae yeast
and L. donovani parasite, respectively.
Fas and mitochondria have been involved previously in
the ET-18-OCH3  apoptotic response (9–12, 14). The
translocation of Bid, a Fas mitochondria linker (43, 44),
into Fas-containing membrane rafts suggests that Bid
could act as a bridge between Fas activation and mito-
chondria in ET-18-OCH3–induced apoptosis, providing a
molecular explanation for the involvement of mitochon-
dria into the Fas-mediated apoptotic response triggered by
ET-18-OCH3. This mechanism of action brings together
Fas- and mitochondria-mediated signaling pathways po-
tentiating the efficient triggering of apoptosis. Our data
also indicate that procaspase-10 is activated at a higher ex-
tent than procaspase-8 in ET-18-OCH3–treated cells,
suggesting that caspase-10 could be a relatively stronger
Figure 9. ET-18-OCH3 spares normal human hepatocytes. Human
hepatocytes were untreated (C) or treated with 200 ng/ml cytotoxic anti-
Fas CH-11 mAb or with 10 or 20  M ET-18-OCH3 for 24 h, and then
apoptosis was determined by flow cytometry. Data shown are means  
SD of three independent determinations.Gajate et al. 363
mediator than caspase-8 in the apoptotic response induced
by ET-18-OCH3.
Our data indicate that ET-18-OCH3 is rapidly incorpo-
rated into membrane rafts forming caps at the cell surface,
and then Fas and downstream Fas effectors are recruited
into rafts enriched in apoptotic signaling molecules, which
seem to function as concentrating platforms for receptors,
adaptors, and signaling molecules required to elicit an effi-
cient apoptotic response. Thus, the herein reported recruit-
ment of Fas and downstream Fas effectors into membrane
rafts can provide a mechanism for amplifying Fas signaling
by reorganization of membrane microdomains and bring-
ing molecules together in a well-defined and reduced space,
facilitating interactions among different signaling molecules
and pathways. Our results demonstrate that rafts can be
targets for therapeutic intervention. However, the results
reported here also indicate that clustering of rafts in the
absence of Fas is not sufficient to mount an apoptotic re-
sponse in ET-18-OCH3–treated cells. Thus, rafts behave as
recruitment platforms to facilitate and potentiate down-
stream signaling events, and Fas functions as a critical trig-
ger of the apoptotic process.
This ET-18-OCH3–mediated aggregation of Fas-con-
taining raft membrane domains resembles ceramide-medi-
ated clustering of Fas. Initial activation of Fas by FasL leads
to caspase-8–mediated SMase translocation into membrane
rafts and its subsequent activation-generating ceramide,
which in turn promotes Fas clustering in ceramide-enriched
membrane platforms and further Fas activation (15, 24).
Ceramide-mediated Fas clustering requires ligand-bound
Fas as C16-ceramide is unable to trigger Fas clustering in the
absence of stimulatory anti-Fas antibody or FasL (24). Here
we failed to detect SMase activation or any increase in cer-
amide production after ET-18-OCH3 treatment, and the
action of ET-18-OCH3 is independent of FasL (12). Fur-
thermore, we found ceramide inhibited ET-18-OCH3–
induced apoptosis (unpublished data). Overall, these data
suggest that the action of ET-18-OCH3 is independent of
SMase-derived ceramide.
Our data indicate that ET-18-OCH3 is the first drug that
selectively activates Fas in tumor cells and also constitutes
the first death receptor–engaged drug without harmful side
effects. These features are of great potential in cancer ther-
apy. Elucidation of the mechanisms regulating ET-18-
OCH3 uptake, intracellular Fas activation, and the forma-
tion of rafts enriched in apoptotic signaling molecules, may
lead to the development of novel strategies in cancer ther-
apy with no adverse effects on normal tissues. ET-18-
OCH3, beyond its putative clinical importance, is an inter-
esting model compound for the development of more
selective anticancer drugs.
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